CanSino Biologics Inc. announced that, the Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia®) developed by the Group has obtained Halal Decree by the Assessment Institute for Foods, Drugs and Cosmetics of Majelis Ulama Indonesia (LPPOM MUI). Indonesia has the largest Muslim population in the world, with around 87% of its population practicing Islam. Pursuant to the public data, Indonesia has a total population of approximately 278 million, ranking the fourth largest population in the world in 2022.

According to relevant regulations of Indonesia government, pharmaceutical products in Indonesia market shall be certified by Halal Product Assurance Body (BPJPH) to obtain the Halal Decree. The Halal Decree signifies that Convidecia® has gained access to the globally recognized Muslim market, which is conducive to the progress of the Company's internationalization. Convidecia ® is developed based on the viral vector platform of the Company.

Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air®), TB Booster and Recombinant Zoster Vaccine are also developed based on the same technology platform. These vaccines have the potential to obtain Halal Decree in the future, which will enable the Company to further open the market in Muslim countries and regions.